Antibody Information

Antibody ID

Antibody Name

Antibody Type

Monoclonal antibody (mAb)

Antibody Subtype

Humanized IgG1-kappa

Antigen Name

Receptor tyrosine-protein kinase erbB-3 (ERBB3)

Antigen Info

Click to Show/Hide the Sequence Information of This Antibody

General Information of This Antibody

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

AMT-562 [Phase 1]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Patients Enrolled	Eligible patients must be ≥18 years with histologically confirmed unresectable advanced solid tumors, prior systemic therapy failure, ECOG 0-1, adequate organ function, and at least one measurable lesion. Key exclusions include CNS metastasis, unresolved toxicities from prior therapy, active infections, recent major surgery or radiotherapy, significant cardiac disease, or concurrent investigational trial participation. Pregnancy, substance abuse, and uncontrolled medical/psychiatric conditions also disqualify candidates. Click to Show/Hide
Administration Dosage	Administered AMT-562 for injection intravenously
*Related Clinical Trial*
NCT Number	NCT06199908	Clinical Status	PHASE1
Clinical Description	First-in-Human, Phase 1 Study of AMT-562 in Patients With Advanced Solid Tumors
Primary Endpoint	The study assesses safety endpoints including Dose Limiting Toxicities (DLTs), Adverse Events (AEs), and Serious Adverse Events (SAEs), evaluated for type, incidence, and severity over a 24-month timeframe.
Other Endpoint	Pharmacokinetic parameters such as Cmax, Tmax, AUC, t1/2, and Anti-Drug Antibodies (ADAs) are measured, alongside efficacy outcomes including ORR, DCR, PFS, TTR, and DOR, all assessed per RECIST v1.1 over 24 months.

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 71.80%	Low HER3 expression (HER3+)
Method Description	AMT-562 (10 mg/kg, day 1) induces efficient tumor cell killing in cell line-derived models of Pancreatic cancer cell with HER3 expression with high expression.
In Vivo Model	Pancreatic cancer PDX model (PDX: PDX-200930)
Experiment 2 Reporting the Activity Date of This ADC				[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Low HER3 expression (HER3+)
Method Description	AMT-562 (10 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of Pancreatic cancer cell with HER3 expression with high expression.
In Vivo Model	Pancreatic cancer PDX model (PDX: PDX-361319)
Experiment 3 Reporting the Activity Date of This ADC				[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Low HER3 expression (HER3+)
Method Description	AMT-562 (10 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of Pancreatic cancer cell with HER3 expression with high expression.
In Vivo Model	Squamous cell carcinoma PDX model (PDX: PDX-361318)

References

Ref 1	AMT-562 in Patients With Selected Advanced Solid Tumors
Ref 2	AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors. Mol Cancer Ther. 2023 Jun 11:MCT-23-0198. doi: 10.1158/1535-7163.MCT-23-0198. Online ahead of print.